Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.88 USD | +4.72% | +3.83% | +7.49% |
01/04 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
27/03 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.49% | 445M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon Concludes Enrollment in Phase 2 Trial of Geographic Atrophy Drug ANX007